ArticleNeoplasia (New York, N.Y.)
Suppression of angiogenesis and therapy of human colon cancer liver metastasis by systemic administration of interferon-alpha.
Article in Neoplasia (New York, N.Y.). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 72 citations in OpenAlex.
- ECOG phase II trial of graded-dose peginterferon α-2b in patients with metastatic melanoma overexpressing basic fibroblast growth factor (E2602).Clinical cancer research : an official journal of the American Association for Cancer Research · 2013Trial
- Semaphorin 6D drives anti-tumor type I interferon responses to reprogram the tumor microenvironment in colorectal cancer.Cell death & disease · 2026Article
- A targeted MAVS fusion protein for controlled innate immune activation and antitumor therapy.Oncoimmunology · 2025Article
- Patient-reported symptom burden and circulating cytokines undergoing chemotherapy: a pilot study in patients with ovarian cancer.Journal of gynecologic oncology · 2025Article
- Review
- Cannabinoids, Medical Cannabis, and Colorectal Cancer Immunotherapy.Frontiers in medicine · 2021Review
- Article
- Tumor Site-Dependent Transport Properties Determine Nanotherapeutics Delivery and Its Efficacy.Translational oncology · 2019Article
- Role of Type I and II Interferons in Colorectal Cancer and Melanoma.Frontiers in immunology · 2017Review
- Serum biomarkers for personalization of nanotherapeutics-based therapy in different tumor and organ microenvironments.Cancer letters · 2014Article
- The detrimental effects of IFN-α on vasculogenesis in lupus are mediated by repression of IL-1 pathways: potential role in atherogenesis and renal vascular rarefaction.Journal of immunology (Baltimore, Md. : 1950) · 2010Article
- Ingested Type I Interferon-State of the Art as Treatment for Autoimmunity Part 2.Pharmaceuticals (Basel, Switzerland) · 2010Article
- Article
- Enhancing the anti-angiogenic action of histone deacetylase inhibitors.Molecular cancer · 2007Article
- Interferon-alpha after autologous stem cell transplantation in pediatric patients with advanced Hodgkin's lymphoma.Bone marrow transplantation · 2006Article
- Angiogenesis in a human neuroblastoma xenograft model: mechanisms and inhibition by tumour-derived interferon-gamma.British journal of cancer · 2006Article
- The relation between c-myc expression and interferon sensitivity in uveal melanoma.The British journal of ophthalmology · 2004Article
- Surrogate markers in antiangiogenesis clinical trials.British journal of cancer · 2003Review
- Mechanism and its regulation of tumor-induced angiogenesis.World journal of gastroenterology · 2003Review
- Strong inhibition of Ewing tumor xenograft growth by combination of human interferon-alpha or interferon-beta with ifosfamide.Oncogene · 2002Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 2 countries.
Funding
Abstract
The purpose of this study was to determine whether systemic administration of interferon-alpha (IFN-alpha) can inhibit liver metastasis produced in nude mice by human colon cancer cells. KM12L4 (IFN-alpha-sensitive) or KM12L4 IFN(R) (IFN-alpha-resistant) cells were injected into the spleen of nude mice. Seven days later, the mice were treated with subcutaneous (s.c.) injections of IFN-alpha (70,000 units/week) at different dosing schedules (1, 2, or 7 times/week). Significant inhibition of tumor growth, vascularization and expression of basic fibroblast growth factor (bFGF) or matrix metalloproteinase-9 (MMP-9) mRNA and protein occurred in mice given daily injections of IFN-alpha. Kinetic analysis of therapy showed that daily s.c. administrations of 10,000 units of IFN-alpha induced apoptosis in liver metastasis-associated endothelial cells, followed by inhibition of tumor cell division and apoptosis of tumor cells. These data suggest that the antiangiogenic activity of IFN-alpha-2a depends on frequent administration of the optimal biologic dose.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.